UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
FORM 10-Q
 
    ☒
☒QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
 
For the quarterly period ended September 30, 2018March 31, 2019
 
☐
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from ________to________
 
 
Commission file number 0-6658
 
SCIENTIFIC INDUSTRIES, INC.
(Exact Name of Registrant as specified in Its Charter)
 
 
Delaware04-2217279
(State or other jurisdiction of incorporation or organization)(I.R.S. Employer Identification No.)
  
80 Orville Drive, Suite 102, Bohemia, New York11716
(Address of principal executive offices)(Zip Code)
 
(631) 567-4700
(Registrant’s telephone number, including area code)
 
Not Applicable
(Former name, former address and former fiscal year, if changed since last report)
 
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports) and (2) has been subject to such filing requirements for the past 90 days.
☒ Yes    ☒☐ No           ☐

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Website, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). ☒ Yes    ☒ No ☐☐No
 
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer”, and “smaller reporting company”, and “emerging growth company” in Rule 12b-2 of the Exchange Act.
 
Large accelerated filer ☐
Accelerated filer ☐
Non-accelerated filer ☐(Do not check if a smaller reporting company)
Smaller reporting company ☒
 
Emerging Growth company☐
 
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
 
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act)
Yes☐ No ☒
 

The number of shares outstanding of the registrant’s common stock, par value $.05 per share (“Common Stock”) as of October 31, 2018May 3, 2019 is 1,494,112 shares.
 

 
 
 
SCIENTIFIC INDUSTRIES, INC.
 
Table of Contents
 
PART I - Financial Information 
   
Item 11..
CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) 
   
 Condensed Consolidated Balance Sheets31
   
 Condensed Consolidated Statements of Operations42
   
 Condensed Consolidated Statements of Comprehensive Income (Loss)53
Condensed Consolidated Statements of Changes in Shareholders' Equity
4
   
 Condensed Consolidated Statements of Cash Flows6
   
 Notes to Unaudited Condensed Consolidated Financial Statements7
   
Item 2.
MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS13
Item 4.
CONTROLS AND PROCEDURES1415
   
Item 4.
CONTROLS AND PROCEDURES17


PART II - Other Information
   
Item 6.
EXHIBITS AND REPORTS ON FORM 8-K1417
   
SIGNATURE
 1518
 
 
 2
 

 
PART I – FINANCIAL INFORMATION
IItemtem 1. Financial Statements
SCIENTIFIC INDUSTRIES, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED BALANCE SHEETS
 
ASSETS
 
 
September 30, 2018
 
 
June 30, 2018
 
 
March 31, 2019
 
 
June 30, 2018
 
Current assets:
 
(Unaudited)
 
 
 
 
 
(Unaudited)
 
 
 
 
Cash and cash equivalents
 $1,507,300 
 $1,053,100 
 $1,354,200 
 $1,053,100 
Investment securities
  322,700 
  314,700 
  325,100 
  314,700 
Trade accounts receivable, less allowance for doubtful accounts of $11,600 at September 30, 2018 and June 30, 2018
  1,190,000 
  1,444,100 
Trade accounts receivable, less allowance for doubtful accounts of $11,600 at March 31, 2019
and June 30, 2018
  2,000,400 
  1,444,100 
Contract assets, current
  67,100 
  278,200 
  422,300 
  278,200 
Inventories
  2,301,000 
  2,267,900 
  2,671,300 
  2,267,900 
Prepaid expenses and other current assets
  67,000 
  33,500 
  65,800 
  33,500 
Total current assets
  5,455,100 
  5,391,500 
  6,839,100 
  5,391,500 
    
    
Property and equipment, net
  185,600 
  199,500 
  281,200 
  199,500 
    
    
Intangible assets, net
  278,900 
  338,700 
  189,800 
  338,700 
    
    
Goodwill
  705,300 
  705,300 
    
    
Contract assets, less current portion
  245,400 
  - 
  245,400 
    
    
Other assets
  52,500 
  52,500 
    
    
Deferred taxes
  386,600 
  392,600 
  463,400 
  392,600 
    
    
Total assets
 $7,309,400 
 $7,325,500 
 $8,531,300 
 $7,325,500 
LIABILITIES AND SHAREHOLDERS’ EQUITY
Current liabilities:
 
 
 
 
 
 
Accounts payable
 $362,600 
 $428,000 
 $451,400 
 $428,000 
Accrued expenses and taxes, current portion
  541,900 
  657,700 
  806,500 
  657,700 
Bank line of credit
  50,000 
  - 
Contract liabilities
  75,900 
  63,800 
  227,800 
  63,800 
Contingent consideration, current portion
  118,000 
  311,000 
  118,000 
Dividends payable
  74,700 
  - 
Notes payable
  4,200 
  5,800 
  700 
  5,800 
Total current liabilities
  1,177,300 
  1,273,300 
  1,847,400 
  1,273,300 
    
    
Accrued expenses, less current portion
  60,000 
  - 
  60,000 
Contingent consideration payable, less current portion
  290,000 
  664,000 
  290,000 
    
    
Total liabilities
  1,527,300 
  1,623,300 
  2,511,400 
  1,623,300 
Shareholders’ equity:
    
    
Common stock, $.05 par value; authorized 7,000,000 shares; issued 1,513,914 shares, outstanding 1,494,112 shares at September 30, 2018 and June 30, 2018
  75,700 
Common stock, $.05 par value; authorized 7,000,000 shares; issued 1,513,914, outstanding 1,494,112, at March 31, 2019 and June 30, 2018
  75,700 
Additional paid-in capital
  2,554,600 
  2,545,900 
  2,575,800 
  2,545,900 
Accumulated other comprehensive gain (loss)
  (16,900)
  1,200 
  (12,300)
  1,200 
Retained earnings
  3,221,100 
  3,131,800 
  3,433,100 
  3,131,800 
  5,834,500 
  5,754,600 
  6,072,300 
  5,754,600 
Less common stock held in treasury at cost, 19,802 shares
  52,400 
  52,400 
    
    
    
Total shareholders’ equity
  5,782,100 
  5,702,200 
  6,019,900 
  5,702,200 
    
    
Total liabilities and shareholders’ equity
 $7,309,400 
 $7,325,500 
 $8,531,300 
 $7,325,500 
 
See notes to unaudited condensed consolidated financial statements.
 
  3
 1
 
 
SCIENTIFIC INDUSTRIES, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED)
 
 
 
For the Three Month Period Ended September 30, 2018
 
 
For the Three Month Period Ended September 30, 2017
 
 
 
 
 
 
 
 
Revenues
 $2,038,600 
 $1,280,800 
 
    
    
Cost of revenues
  1,092,900 
  829,100 
 
    
    
Gross profit
  945,700 
  451,700 
 
    
    
Operating expenses:
    
    
General and administrative
  416,500 
  428,400 
Selling
  236,100 
  201,000 
Research and development
  117,400 
  129,100 
 
    
    
Total operating expenses
  770,000 
  758,500 
 
    
    
Income (loss) from operations
  175,700 
  (306,800)
 
    
    
Other income (expense):
    
    
Other income, net
  2,200 
  400 
Interest expense
  (400)
  (100)
 
    
    
Total other income, net
  1,800 
  300 
 
    
    
Income (loss) before income tax expense (benefit)
  177,500 
  (306,500)
 
    
    
Income tax expense (benefit):
    
    
Current
  29,500 
  (63,700)
Deferred
  6,000 
  (10,200)
 
    
    
Total income tax expense (benefit)
  35,500 
  (73,900)
 
    
    
Net income (loss)
 $142,000 
 $(232,600)
 
    
    
Basic earnings (loss) per common share
 $.10 
 $(.16)
 
    
    
Diluted earnings (loss) per common share
 $.09 
 $(.16)
 
 
For the Three Month Period Ended
March 31,
 
 
For the Three Month Period Ended
March 31,
 
 
For the Nine Month Period Ended
March 31,
 
 
For the Nine Month Period Ended
March 31,
 
 
 
2019
 
 
2018
 
 
2019
 
 
2018
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Revenues
 $3,053,500 
 $2,099,300 
 $7,255,300 
 $5,272,600 
 
    
    
    
    
Cost of revenues
  1,972,400 
  1,331,500 
  4,252,700 
  3,287,300 
 
    
    
    
    
Gross profit
  1,081,100 
  767,800 
  3,002,600 
  1,985,300 
 
    
    
    
    
Operating expenses:
    
    
    
    
General and administrative
  492,400 
  470,200 
  1,371,000 
  1,306,600 
Selling
  282,100 
  263,800 
  766,400 
  679,500 
Research and development
  120,900 
  117,700 
  347,600 
  379,700 
 
    
    
    
    
Total operating expenses
  895,400 
  851,700 
  2,485,000 
  2,365,800 
 
    
    
    
    
Income (loss) from operations
  185,700 
  (83,900)
  517,600 
  (380,500)
 
    
    
    
    
Other income (expense):
    
    
    
    
Interest income
  300 
  - 
  3,100 
  5,600 
    Other income, net
  8,100 
  500 
  600 
  1,900 
    Interest expense
  (600)
  (500)
  (1,400)
  (1,100)
 
    
    
    
    
Total other income, net
  7,800 
  - 
  2,300 
  6,400 
 
    
    
    
    
Income (loss) before income tax expense (benefit)
  193,500 
  (83,900)
  519,900 
  (374,100)
 
    
    
    
    
Income tax expense (benefit):
    
    
    
    
    Current
  179,700 
  9,700 
  233,600 
  17,800 
Deferred
  (79,800)
  (55,900)
  (67,800)
  (40,400)
 
    
    
    
    
Total income tax expense (benefit)
  99,900 
  (46,200)
  165,800 
  (22,600)
 
    
    
    
    
Net income (loss)
 $93,600 
 $(37,700)
 $354,100 
 $(351,500)
 
    
    
    
    
Basic earnings (loss) per common share
 $.06 
 $(.03)
 $.24 
 $(.24)
 
    
    
    
    
Diluted earnings (loss) per common share
 $.06 
 $(.03)
 $.23 
 $(.24)
 
    
    
    
    
Cash dividends declared per common share
 $- 
 $- 
 $.05 
 $- 
See notes to unaudited condensed consolidated financial statements.
 2
SCIENTIFIC INDUSTRIES, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) (UNAUDITED)
 
 
For the Three Month Period Ended
March 31,
 
 
For the Three Month Period Ended
March 31
 
 
For the Nine Month Period Ended
March 31,
 
 
For the Nine Month Period Ended
March 31,
 
 
 
2019
 
 
2018
 
 
2019
 
 
2018
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Net income (loss)
 $93,600 
 $(37,700)
 $354,100 
 $(351,500)
 
    
    
    
    
Other comprehensive income (loss):
    
    
    
    
Unrealized holding gain (loss) arising during period net of tax
  7,500 
  (5,100)
  (13,500)
  (900)
 
    
    
    
    
 
    
    
    
    
Comprehensive income (loss)
 $101,100 
 $(42,800)
 $340,600 
 $(352,400)
See notes to unaudited condensed consolidated financial statements.
  3
  CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY (UNAUDITED)

 
 
 
 
 
 Additional
 
 
 Accumulated
 Other
 
 
 
 
 
 
 
 
 Total
 
 
 
Common Stock
 
 
 Paid-in
 
 
Comprehensive
 
 
 Retained
 
 
Treasury Stock
 
 
Shareholders’
 
Fiscal Year 2019
 
 Shares 
 
 
 Amount 
 
 
 Capital 
 
 
 Gain (Loss) 
 
 
 Earnings 
 
 
 Shares 
 
 
 Amount 
 
 
 Equity 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Balance, July 1, 2018
  1,513,914 
 $75,700 
 $2,545,900 
 $1,200 
 $3,131,800 
  19,802 
 $52,400 
 $5,702,200 
 
    
    
    
    
    
    
    
    
Cumulative effect of the adoption of
  - 
  - 
  - 
  -  
  22,000 
  -  
  -  
  22,000 
ASU 2016-01 – Financial Instruments
    
    
    
    
    
    
    
    
 
    
    
    
    
    
    
    
    
Net income
  - 
  - 
  - 
  - 
  142,000 
  - 
  - 
  142,000 
 
    
    
    
    
    
    
    
    
Cash dividend declared, $.05
  - 
  - 
  - 
  - 
  (74,700)
  - 
  - 
  (74,700)
 
    
    
    
    
    
    
    
    
Unrealized holding loss on investment securities, net of tax
  - 
  - 
  - 
  (18,100)
  - 
  - 
  - 
  (18,100)
 
    
    
    
    
    
    
    
    
Stock-based compensation
  - 
  - 
  8,700 
  - 
  - 
  - 
  - 
  8,700 
 
    
    
    
    
    
    
    
    
Balance, September 30, 2018
  1,513,914 
  75,700 
  2,554,600 
  (16,900)
  3,221,100 
  19,802 
  52,400 
  5,782,100 
 
    
    
    
    
    
    
    
    
Net income
  - 
  - 
  - 
  - 
  118,400 
  - 
  - 
  118,400 
 
    
    
    
    
    
    
    
    
Unrealized holding loss on investment securities, net of tax
  - 
  - 
  - 
  (2,900)
  - 
  - 
  - 
  (2,900)
 
    
    
    
    
    
    
    
    
Stock-based compensation
  - 
  - 
  9,500 
  - 
  - 
  - 
  - 
  9,500 
 
    
    
    
    
    
    
    
    
Balance, December 31, 2018
  1,513,914 
 75,700 
 2,564,100 
 (19,800)
 3,339,500 
  19,802 
 52,400 
 5,907,100 
 
    
    
    
    
    
    
    
    
Net income
  -  
  -  
  -  
  -  
  93,600 
  -  
  -  
  93,600 
 
    
    
    
    
    
    
    
    
Unrealized holding gain on investment securities, net of tax
  -  
  -  
  -  
  7,500 
  -  
  -  
  -  
  7,500
 
    
    
    
    
    
    
    
    
Stock-based compensation
  -  
  -  
  11,700  
  -  
  -  
  -  
  -  
  11,700 
 
    
    
    
    
    
    
    
    
Balance, March 31, 2019
  1,513,914 
 $75,700 
 $2,575,800 
 $(12,300)
 $3,433,100 
  19,802 
 $52,400 
 $6,019,900 
  See notes to unaudited condensed consolidated financial statements.
 4
  CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY (UNAUDITED)

 
 
 
 
 
 Additional
 
 
 Accumulated
 Other
 
 
 
 
 
 
 
 
 Total
 
 
 
Common Stock
 
 
 Paid-in
 
 
Comprehensive
 
 
 Retained
 
 
Treasury Stock
 
 
Shareholders’
 
Fiscal Year 2018
 
 Shares 
 
 
 Amount 
 
 
 Capital 
 
 
 Gain (Loss) 
 
 
 Earnings 
 
 
 Shares 
 
 
 Amount 
 
 
 Equity 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Balance, July 1, 2017
  1,513,914 
 $75,700 
 $2,515,900 
 $(3,500)
 $3,292,300 
  19,802 
 $52,400 
 $5,828,000 
 
    
    
    
    
    
    
    
    
Net loss
  - 
  - 
  - 
  - 
  (232,600)
  - 
  - 
  (232,600)
 
    
    
    
    
    
    
    
    
Unrealized holding gain on investment securities, net of tax
  - 
  - 
  - 
  2,600 
  - 
  - 
  - 
  2,600 
 
    
    
    
    
    
    
    
    
Stock-based compensation
  - 
  - 
  6,300 
  - 
  - 
  - 
  - 
  6,300 
 
    
    
    
    
    
    
    
    
Balance, September 30, 2017
  1,513,914 
  75,700 
  2,522,200 
  (900)
  3,059,700 
  19,802 
  52,400 
  5,604,300 
 
    
    
    
    
    
    
    
    
Net loss
  - 
  - 
  - 
  - 
  (81,000)
  - 
  - 
  (81,000)
 
    
    
    
    
    
    
    
    
Unrealized holding gain on investment securities, net of tax
  - 
  - 
  - 
  1,600 
  - 
  - 
  - 
  1,600 
 
    
    
    
    
    
    
    
    
Stock-based compensation
  - 
  - 
  6,200 
  - 
  - 
  - 
  - 
  6,200 
 
    
    
    
    
    
    
    
    
Tax benefit of stock option exercised
  -  
  -  
  8,000 
  -  
  -  
  -  
  -  
  8,000 
 
    
    
    
    
    
    
    
    
Balance, December 31, 2017
  1,513,914 
  75,700 
 2,536,400 
 700 
 2,978,700 
  19,802 
 52,400 
   5,539,100
 
    
    
    
    
    
    
    
    
Net loss
  -  
  -  
  -  
  -  
  (37,900)
  -  
  -  
  (37,900)
 
    
    
    
    
    
    
    
    
Unrealized holding loss on investment securities, net of tax
  -  
  -  
  -  
  (5,100)
  -  
  -  
  -  
  (5,100)
 
    
    
    
    
    
    
    
    
Stock-based compensation
  -  
  -  
  6,100 
  -  
  -  
  -  
  -  
  6,100 
 
    
    
    
    
    
    
    
    
Balance, March 31, 2018
  1,513,914 
 $75,700 
 $2,542,500 
 $(4,400)
 $2,940,800 
  19,802 
 $52,400 
 $5,502,200 
 
    
    
    
    
    
    
    
    
  See notes to unaudited condensed consolidated financial statements.
 5

SCIENTIFIC INDUSTRIES, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)
 
 
For the Nine Month Period Ended
March 31,
 
 
For the Nine Month Period Ended
March 31,
 
 
 
2019
 
 
2018
 
Operating activities:
 
 
 
 
 
 
Net income (loss)
 $354,100 
 $(351,500)
Adjustments to reconcile net income (loss) to net
cash provided by (used in) operating activities:
    
    
           Loss on sale of investments
  5,000 
  - 
Depreciation and amortization
  218,200 
  230,100 
Deferred income tax expense
  (70,800)
  (39,400)
Unrealized holding gain on investments
  (4,200)
 - 
Income tax benefit of stock options exercised
  - 
  8,000 
Stock-based compensation
  29,900 
  18,600 
Change in fair value of contingent consideration
  567,000 
  445,700 
Changes in operating assets and liabilities:
    
    
Trade accounts receivable
  (556,300)
  (227,700)
Contract assets
  101,300 
 - 
Inventories
  (403,400)
  (740,400)
Prepaid and other current assets
  (32,300)
  (12,000)
Accounts payable
  23,400 
  255,200 
Contract liabilities
  164,000 
  356,000 
Accrued expenses and taxes
  88,800 
  (92,800)
 
    
    
Total adjustments
  130,600 
  201,300 
 
    
    
Net cash provided by (used in) operating activities
  484,700 
  (150,200)
 
    
    
Investing activities:
    
    
Sale of investment securities, available-for-sale
  72,400 
  - 
Purchase of investment securities, available-for-sale
  (75,200)
  (14,500)
Capital expenditures
  (129,600)
  (70,500)
Purchase of intangible assets
  (21,400)
  (3,600)
 
    
    
Net cash used in investing activities
  (153,800)
  (88,600)
 
    
    
Financing activities:
    
    
Line of credit proceeds
  50,000 
  40,000 
Payments for contingent consideration
  - 
  (142,700)
Cash dividend declared and paid
  (74,700)
  - 
Principal payments on notes payable
  (5,100)
  (5,000)
 
    
    
Net cash used in financing activities
  (29,800)
  (107,700)
 
    
    
Net increase (decrease) in cash and cash equivalents
  301,100 
  (346,500)
 
    
    
Cash and cash equivalents, beginning of year
  1,053,100 
  1,025,100 
 
    
    
Cash and cash equivalents, end of period
 $1,354,200 
 $678,600 
 
    
    
Cash paid during the period for:
    
    
Income taxes
 $59,200 
 $16,000 
Interest
  1,400 
  1,100 
 
See notes to unaudited condensed consolidated financial statements.
 
 46
 
 
SCIENTIFIC INDUSTRIES, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN COMPREHENSIVE INCOME (LOSS) (UNAUDITED)
 
 
For the Three Month Period Ended September 30, 2018
 
 
For the Three Month Period Ended September 30, 2017
 
 
 
 
 
 
 
 
Net income (loss)
 $142,000 
 $(232,600)
 
    
    
Other comprehensive income (loss):
    
    
Unrealized holding gain (loss)
    
    
arising during period,
    
    
net of tax
  (18,100)
  2,600 
 
    
    
Comprehensive income (loss)
 $123,900 
 $(230,000)
See notes to unaudited condensed consolidated financial statements.
  5
SCIENTIFIC INDUSTRIES, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)
 
 For the Three Month Period Ended September 30,  2018
 For the Three Month Period Ended September 30,  2017
Operating activities:
   
   
Net income (loss)
 $142,000 
 $(232,600)
Adjustments to reconcile net income (loss) to net
cash provided by operating activities:
    
    
Depreciation and amortization
  75,900 
  77,100 
Deferred income taxes
  6,000 
  (10,200)
Stock-based compensation
  8,700 
  6,200 
Loss on sale of investments
  5,000 
  - 
Unrealized holding gain of investments
  (6,400)
  - 
Changes in operating assets and liabilities:
    
    
Trade accounts receivable
  254,100 
     276,800
Contract assets, current
  211,100 
     175,500
Inventories
  (33,100)
  (366,000)
Prepaid and other current assets
  (33,500)
  (90,500)
Accounts payable
  (65,400)
  237,700 
Contract liabilities
  12,100 
  17,000 
Accrued expenses and taxes
  (115,800)
  12,600 
 
    
    
Total adjustments
  318,700 
  336,200 
 
    
    
Net cash provided by operating activities
  460,700 
  103,600 
 
    
    
Investing activities:
    
    
Purchase of investment securities, available for sale
  (75,200)
  (9,300)
Redemption of investment securities, available for sale
  72,500 
  - 
Capital expenditures
  (900)
  (31,500)
Purchase of other intangible assets
  (1,300)
  (700)
 
    
    
Net cash used in investing activities
  (4,900)
  (41,500)
 
    
    
Financing activities:
    
    
Payments for contingent consideration
  - 
  (142,700)
Principal payments on notes payable
  (1,600)
  (1,600)
 
    
    
Net cash used in financing activities
  (1,600)
  (144,300)
 
    
    
Net increase (decrease) in cash and cash equivalents
  454,200 
  (82,200)
 
    
    
Cash and cash equivalents, beginning of year
  1,053,100 
  1,025,100 
 
    
    
Cash and cash equivalents, end of period
 $1,507,300 
 $942,900 
 
    
    
 
    
    
Supplemental disclosures:
    
    
 
    
    
Cash paid during the period for:
    
    
Income taxes
 $500 
 $15,000 
Interest
  400 
  100 
See notes to unaudited condensed consolidated financial statements.
  6
SCIENTIFIC INDUSTRIES, INC. AND SUBSIDIARIES
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
 
General:The accompanying unaudited interim condensed consolidated financial statements are prepared pursuant to the Securities and Exchange Commission’s rules and regulations for reporting on Form 10-Q. Accordingly, certain information and footnotes required by accounting principles generally accepted in the United States for complete financial statements are not included herein. The Company believes all adjustments necessary for a fair presentation of these interim statements have been included and that they are of a normal and recurring nature. These interim statements should be read in conjunction with the Company’s financial statements and notes thereto, included in its Annual Report on Form 10-K, for the fiscal year ended June 30, 2018.30,2018. The results for the three months and nine months ended September 30, 2018,March 31, 2019  are not necessarily an indication of the results for the full fiscal year ending June 30, 2019.
 
1. Summary of Significant Accounting Policies
 
Principles of Consolidation
 
The accompanying consolidated financial statements include the accounts of Scientific Industries, Inc., Altamira Instruments, Inc. (“Altamira”), a Delaware corporation and wholly-owned subsidiary, and Scientific Bioprocessing, Inc. (“SBI”), a Delaware corporation and wholly-owned subsidiary, and Scientific Packaging Industries, Inc., an inactive wholly-owned subsidiary (all collectively referred to as the “Company”). All material intercompany balances and transactions have been eliminated.
 
Recent Accounting Pronouncements
 
In February 2016, the FASB issued ASU No. 2016-02, “Leases”“Leases” (Topic 842). The FASB issued this update to increase transparency and comparability among organizations by recognizing lease assets and lease liabilities on the balance sheet and disclosing key information about leasing arrangements. The updated guidance is effective for annual periods beginning after December 15, 2018, including interim periods within those fiscal years. Early adoption of the update is permitted. The Company is currently evaluating the impact of the new standard.
 
In July 2017, the FASB issued ASU 2017-11, “Earnings Per Share (Topic 260), Distinguishing Liabilities from Equity (Topic 480) and Derivatives and Hedging (Topic 815): I. Accounting for Certain Financial Instruments with Down Round Features; II. Replacement of the Indefinite Deferral for Mandatorily Redeemable Financial Instruments of Certain Nonpublic Entities and Certain Mandatorily Redeemable Noncontrolling Interests with a Scope Exception”. Part I of this update addresses the complexity of accounting for certain financial instruments with down round features. Down round features are features of certain equity-linked instruments (or embedded features) that result in the strike price being reduced on the basis of the pricing of future equity offerings. Current accounting guidance creates cost and complexity for entities that issue financial instruments (such as warrants and convertible instruments) with down round features that require fair value measurement of the entiretheentire instrument or conversion option. Part II of this update addresses the difficulty of navigating Topic 480, Distinguishing Liabilities from Equity, because of the existence of extensive pending content in the FASB Accounting Standards Codification. This pending content is the result of the indefinite deferral of accounting requirements about mandatorily redeemable financial instruments of certain nonpublic entities and certain mandatorily redeemable noncontrolling interests. The amendments in Part II of this update do not have an accounting effect. This ASU is effective for fiscal years, and interim periods within those years, beginning after December 15, 2018.  The Company is evaluatingexpects that the effect thatadoption of this ASU 2017-11 will have on itsno material inpact to the Company's financial statements and related disclosures.statement.

Adopted Accounting Pronouncements
In January 2016, the FASB issued ASU No. 2016-01, “Financial Instruments - Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities”. The update addresses certain aspects of recognition, measurement, presentation and disclosure of financial instruments. For public business entities, the amendments in this update are effective for fiscal years beginning after December 15, 2017, including interim periods within those fiscal years. Early adoption is permitted only for certain portions of the ASU related to financial liabilities. The Company adopted this pronouncement during the interim period September 30, 2018, which resulted in a $22,000 cumulative effect adjustment to retained earnings in the condensed consolidated balance sheet as of the beginning of the fiscal year of adoption.
 
In April 2016, the FASB issued ASU No. 2016-10, “Revenue from Contracts with Customers: Identifying Performance Obligations and Licensing (Topic 606)”. In March 2016, the FASB issued ASU No. 2016-08, “Revenue from Contracts with Customers: Principal versus Agent Considerations (Reporting Revenue Gross verses Net) (Topic 606)”. These amendments provide additional clarification and implementation guidance on the previously issued ASU 2014-09, “Revenue from Contracts with Customers”. The amendments in ASU 2016-10 provide clarifying guidance on materiality of performance obligations;obligations, evaluating distinct performance obligations;obligations, treatment of shipping and handling costs;costs, and determining whether an entity’s promise to grant a license provides a customer with either a right to use an entity’s intellectual property or a right to access an entity’s intellectual property. The amendments in ASU 2016-08 clarify how an entity should identify the specified good or service for the principal versus agent evaluation and how it should apply the control principle to certain types of arrangements. The Company adopted the provisions of these pronouncements on July 1, 2018, using the modified retrospective approach. Revenue from the Company’s sales continue to generally be recognized when products are shipped (i.e. point in time). As such, the adoption of ASU 2016-10 had no material impact to the Company’s financial position or results of operations; however, the Company has now presented the disclosures required by this new standard, refer to Note 2.
 
In August 2016, the FASB issued ASU 2016-15, “Classification of Certain Cash Receipts and Cash Payments”. This update provides guidance on how to record eight specific cash flow issues. This update is effective for fiscal years beginning after December 15, 2017, and interim periods within those fiscal years. Early adoption is permitted and a retrospective transition method to each period should be presented. The adoption of this ASU had no impact on the Company’s consolidated financial statements.
 
In November 2016, the FASB issued ASU 2016-18, “Statement of Cash Flows (Topic 230)”, requiring that the statement of cash flows explain the change in the total cash, cash equivalents, and amounts generally described as restricted cash or restricted cash equivalents. This guidance is effective for fiscal years, and interim reporting periods therein, beginning after December 15, 2017 with early adoption permitted. The provisions of this guidance are to be applied using a retrospective approach which requires application of the guidance for all periods presented. The adoption of this ASU had no impact on the Company’s consolidated financial statements.
 
 7
 
 

Reclassification
 
Trade accounts receivable, current of $67,100$422,300 and $278,200, and trade accounts receivable, long term of $245,400 for both periodsthe year ended June 30, 2018 were reclassified to contract assets, current; and contract assets, less current portion, respectively, on the balance sheet as of September 30,
March 31, 2019 and June 30, 2018. Customer advances of $63,800 were reclassified to contract liabilities as of September 30,March 31, 2019 and June 30, 2018.
 
2. Revenue
 
The Company’s revenues are comprised of product sales (Benchtop Laboratory Equipment Operations) as well as products and related services such as installation and training as is customary for its customers of the Catalyst Research Instruments Operations. In addition, the Company’s Bioprocessing Systems Operations’ revenues are comprised of royalty revenues. All revenue is recognized when the Company satisfies its performance obligation(s) under the contract (either implicit or explicit) by transferring the promised product or service to its customer either when (or as) its customer obtains control of the product or service. A performance obligation is a promise in a contract to transfer a distinct product or service to a customer. A contract’s transaction price is allocated to each distinct performance obligation. The majority of the Company’s contracts have a single performance obligation, as the promise to transfer products or services is not separately identifiable from other promises in the contract and, therefore, not distinct. For contracts with multiple performance obligations, the Company allocates the contract’s transaction price to each performance obligation using the Company’s best estimate of standalone selling price for each distinct product or service in the contract, which is generally based on an observable price.
 
Revenue is measured as the amount of consideration the Company expects to receive in exchange for transferring products or providing services. As such, revenue is recorded net of returns, allowances, customer discounts, and incentives. Revenue from the Bioprocessing Systems Operations are recognized over time based on Management’s judgment and estimates.
 
 8

3. Segment Information and Concentrations
 
The Company views its operations as three segments: the manufacture and marketing of standard benchtop laboratory equipment for research in university, hospital and industrial laboratories sold primarily through laboratory equipment distributors and laboratory and pharmacy balances and scales (“Benchtop Laboratory Equipment Operations”), the manufacture and marketing of custom-made catalyst research instruments for universities, government laboratories, and chemical and petrochemical companies sold on a direct basis (“Catalyst Research Instruments Operations”) and the design and marketing of bioprocessing systems and products and related royalty income (“Bioprocessing Systems”).
 
Segment information is reported as follows:
 
 
 Benchtop Laboratory Equipment 
 Catalyst Research Instruments 
 Bioprocessing
Systems 
 Corporate
And Other 
 Consolidated 
 
   
   
   
   
   
Three Months Ended September 30, 2018:
   
   
   
   
   
 
   
   
   
   
   
Revenues
 $1,691,900 
 $217,500 
 $129,200 
 $- 
 $2,038,600 
 
    
    
    
    
    
Foreign Sales
  635,700 
  142,300 
  - 
  - 
  778,000 
 
    
    
    
    
    
    Income (Loss) From Operations
  175,400 
  (62,900)
  63,200 
  - 
  175,700 
 
    
    
    
    
    
Assets
  4,633,500 
  1,343,100 
  623,500 
  709,300 
  7,309,400 
 
    
    
    
    
    
    Long-Lived Asset Expenditures
  2,200 
  - 
  - 
  - 
  2,200 
 
    
    
    
    
    
    Depreciation and Amortization
  66,300 
  200 
  9,400 
  - 
  75,900 
 
 
Benchtop Laboratory Equipment
 
 
Catalyst Research Instruments
 
 
Bioprocessing
Systems
 
 
Corporate
And Other
 
 
Consolidated
 
Three Months Ended March 31, 2019:
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Revenues
 $1,732,400 
 $508,600 
 $812,500 
 $- 
 $3,053,500 
 
    
    
    
    
    
Foreign Sales
  682,300 
  346,400 
  - 
  - 
  1,028,700 
 
    
    
    
    
    
Income (Loss) From
Operations
  57,900 
  (35,200)
  163,000 
  - 
  185,700 
 
    
    
    
    
    
Assets
  4,656,600 
  1,583,100 
  1,503,100 
  788,500 
  8,531,300 
 
    
    
    
    
    
Long-Lived Asset
Expenditures
  132,900 
  1,000 
  2,900 
  - 
  136,800 
 
    
    
    
    
    
Depreciation and
Amortization
  56,500 
  200 
  9,600 
  - 
  66,300 

 
8
 
 
Benchtop Laboratory Equipment
 
 
Catalyst Research Instruments
 
 
Bioprocessing
Systems
 
 
Corporate
And Other
 
 
Consolidated
 
Three Months Ended March 31, 2018:
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Revenues
 $1,550,700 
 $110,700 
 $437,900 
 $- 
 $2,099,300 
 
    
    
    
    
    
Foreign Sales
  620,200 
  105,400 
  - 
  - 
  725,600 
 
    
    
    
    
    
Income (Loss) From
Operations
  78,200 
  (74,400)
  (87,700)
  - 
  (83,900)
 
    
    
    
    
    
Assets
  3,930,600 
  1,680,800 
  893,300 
  853,600 
  7,358,300 
 
    
    
    
    
    
Long-Lived Asset
Expenditures
  4,500 
  - 
  - 
  - 
  4,500 
 
    
    
    
    
    
Depreciation and
Amortization
  67,400 
  (800)
  9,400 
  - 
  76,000 
  
 
 Benchtop Laboratory
Equipment 
 Catalyst Research Instruments 
 Bioprocessing
Systems 
 Corporate
And Other 
 Consolidated 
 
   
   
   
   
   
Three Months Ended September 30, 2017:
   
   
   
   
   
 
   
   
   
   
   
Revenues
 $1,199,400 
 $28,700 
 $52,700 
 $- 
 $1,280,800 
 
    
    
    
    
    
Foreign Sales
  502,300 
  6,400 
  - 
  - 
  508,700 
 
    
    
    
    
    
    Loss From Operations
  (93,900)
  (184,100)
  (28,800)
  - 
  (306,800)
 
    
    
    
    
    
Assets
  4,041,800 
  1,425,400 
  437,000 
  822,700 
  6,726,900 
 
    
    
    
    
    
    Long-Lived Asset Expenditures
  32,200 
  - 
  - 
  - 
  32,200 
 
    
    
    
    
    
    Depreciation and Amortization
  64,900 
  2,800 
  9,400 
  - 
  77,100 

Approximately 49%41% and 46%53% of net sales oftotal benchtop laboratory equipment sales (23% and 39% of total revenues) for the three month periods ended September 30,March 31, 2019 and 2018, and 2017, respectively, were derived from the Company’s main product, the Vortex-Genie 2 mixer, excluding accessories.
 
Approximately 30% and 21% of total benchtop laboratory equipment sales (17% and 16% of total revenues) were derived from the Torbal Scales Division for the three months ended March 31, 2019 and 2018, respectively.
For the three months ended September 30,March 31, 2019 and 2018, and 2017, respectively, three customers accounted in the aggregate for approximately 23%22% and 22%26% of net sales of the Benchtop Laboratory Equipment Operations (19%(12% and 21%19% of the Company’s total revenues)revenues, respectively).
Sales of catalyst research instruments generally comprise a few very large orders averaging approximately $50,000 per order to a limited number of customers, who differ from order to order. Sales to threefive and two customers during the three months ended September 30,March 31, 2019 and 2018, respectively, accounted for approximately 83%86% and 89% of the Catalyst Research Instrument Operations’ revenues and 9%14% and 5% of the Company’s total revenues. There was no significant customer salerevenues, respectively.
 9
 
 
Benchtop Laboratory Equipment
 
 
Catalyst Research Instruments
 
 
Bioprocessing
Systems
 
 
Corporate
And Other
 
 
Consolidated
 
Nine Months Ended March 31, 2019:
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Revenues
 $5,227,500 
 $953,200 
 $1,074,600 
 $- 
 $7,255,300 
 
    
    
    
    
    
Foreign Sales
  2,061,600 
  711,600 
  - 
  - 
  2,773,200 
 
    
    
    
    
    
Income (Loss) From
Operations
  382,100 
  (146,400)
  281,900 
  - 
  517,600 
 
    
    
    
    
    
Assets
  4,656,600 
  1,583,100 
  1,503,100 
  788,500 
  8,531,300 
 
    
    
    
    
    
Long-Lived Asset
Expenditures
  145,900 
  2,200 
  2,900 
  - 
  151,000 
 
    
    
    
    
    
Depreciation and
Amortization
  189,200 
  600 
  28,400 
  - 
  218,200 


 
 
Benchtop Laboratory Equipment
 
 
Catalyst Research Instruments
 
 
Bioprocessing
Systems
 
 
Corporate
And Other
 
 
Consolidated
 
Nine Months Ended March 31, 2018:
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Revenues
 $4,436,300 
 $293,000 
 $543,300 
 $- 
 $5,272,600 
 
    
    
    
    
    
Foreign Sales
  1,937,800 
  114,400 
  - 
  - 
  2,052,200 
 
    
    
    
    
    
Income (Loss) From
Operations
  106,300 
  (361,900)
  (124,900)
  - 
  (380,500)
 
    
    
    
    
    
Assets
  3,930,600 
  1,680,800 
  893,300 
  853,600 
  7,358,300 
 
    
    
    
    
    
Long-Lived Asset
Expenditures
  69,700 
  1,900 
  2,500 
  - 
  74,100 
 
    
    
    
    
    
Depreciation and
Amortization
  199,300 
  2,700 
  28,100 
  - 
  230,100 
Approximately 47% and 51% of total benchtop laboratory equipment sales (34% and 43% of total revenues) for both the nine month periods ended March 31, 2019 and 2018, respectively, were derived from the Company’s main product, the Vortex-Genie 2 mixer, excluding accessories.
Approximately 27% and 22% of total benchtop laboratory equipment sales (19% of total revenues for both periods) were derived from the Torbal Scales Division for both the nine months ended March 31, 2019 and 2018, respectively. For the nine months ended March 31, 2019 and 2018, respectively, three customers accounted for approximately 22% and 15% of net sales of the Benchtop Laboratory Equipment Operations (16% and 12% of the Company’s total revenues), respectively.
Sales of catalyst research instruments generally comprise a few very large orders averaging approximately $50,000 per order to a limited number of customers, who differ from order to order. Sales to eight and three customers during the threenine months ended September 30, 2017.March 31, 2019 and 2018, accounted for approximately 88% and 79% of the Catalyst Research Instrument Operations’ revenues and 12% and 4% of the Company’s total revenues, respectively.
 
 10

4. Fair Value of Financial Instruments
 
The FASB defines the fair value of financial instruments as the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Fair value measurements do not include transaction costs.
 
The accounting guidance also expands the disclosure requirements around fair value and establishes a fair value hierarchy for valuation inputs. The hierarchy prioritizes the inputs into three levels based on the extent to which inputs used in measuring fair value are observable in the market. Each fair value measurement is reported in one of the three levels, which is determined by the lowest level input that is significant to the fair value measurement in its entirety. These levels are described below:
 
Level 1 - Inputs that are based upon unadjusted quoted prices for identical instruments traded in active markets.
 
Level 2 - Quoted prices in markets that are not considered to be active or financial instruments for which all significant inputs are observable, either directly or indirectly.
 
Level 3 - Prices or valuation that require inputs that are both significant to the fair value measurement and unobservable.
 
In valuing assets and liabilities, the Company is required to maximize the use of quoted market prices and minimize the use of unobservable inputs. The Company calculated the fair value of its Level 1 and 2 instruments based on the exchange traded price of similar or identical instruments where available or based on other observable instruments. These calculations take into consideration the credit risk of both the Company and its counterparties. The Company has not changed its valuation techniques in measuring the fair value of any financial assets and liabilities during the period.
 
9
The fair value of the contingent consideration obligations are based on a probability weighted approach derived from the estimates of earn-out criteria and the probability assessment with respect to the likelihood of achieving those criteria. The measurement is based on significant inputs that are not observable in the market, therefore, the Company classifies this liability as Level 3 in the following tables.
 
The following tables set forth by level within the fair value hierarchy the Company’s financial assets that were accounted for at fair value on a recurring basis at September 30, 2018March 31, 2019 and June 30, 2018 according to the valuation techniques the Company used to determine their fair values:
  
   
 Fair Value Measurements Using Inputs Considered as 
 
 
 
 
Fair Value Measurements Using Inputs Considered as
 
 Fair Value at September 30, 2018 
 Level 1 
 Level 2 
 Level 3 
 
Fair Value at March 31, 2019
 
 
Level 1
 
 
Level 2
 
 
Level 3
 
   
 
 
 
Assets:
   
 
 
 
   
 
 
 
Cash and cash equivalents
 $1,507,300 
 $- 
 $1,354,200 
 $- 
Available for sale securities
  322,700 
  - 
Available-for- sale securities
  325,100 
  - 
    
    
Total
 $1,830,000 
 $- 
 $1,679,300 
 $- 
    
    
Liabilities:
    
    
    
    
Contingent consideration
��$408,000 
 $- 
 $408,000 
 $975,000 
 $- 
 $975,000 
 
 
 
 
   
 Fair Value Measurements Using Inputs Considered as 
 
 Fair Value at June 30, 2018 
 Level 1 
 Level 2 
 Level 3 
 
   
   
   
   
Assets:
   
   
   
   
 
   
   
   
   
Cash and cash equivalents
 $1,053,100 
 $1,053,100 
 $- 
 $- 
Available for sale securities
  314,700 
  314,700 
  - 
  - 
 
    
    
    
    
Total
 $1,367,800 
 $1,367,800 
 $- 
 $- 
 
    
    
    
    
Liabilities:
    
    
    
    
 
    
    
    
    
Contingent consideration
 $408,000 
 $- 
 $- 
 $408,000 
 
 
 
 
 
 
Fair Value Measurements Using Inputs Considered as
 
 
 
Fair Value at
June 30, 2018
 
 
Level 1
 
 
Level 2
 
 
Level 3
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Assets:
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cash and cash equivalents
 $1,053,100 
 $1,053,100 
 $- 
 $- 
Available-for-sale securities
  314,700 
  314,700 
  - 
  - 
 
    
    
    
    
Total
 $1,367,800 
 $1,367,800 
 $- 
 $- 
 
    
    
    
    
Liabilities:
    
    
    
    
 
    
    
    
    
Contingent consideration
 $408,000 
 $- 
 $- 
 $408,000 
 11
 
 
The following table sets forth an analysis of changes during the threenine months ended September 30,March 31, 2019 and 2018 and 2017 in Level 3 financial liabilities of the Company:
 
 2018 
 2017 
 
2019
 
 
2018
 
Beginning balance
 $408,000 
 $297,000 
 $408,000 
 $297,000 
Increase in contingent consideration liability
  567,000 
  445,700 
Payments
  - 
  (142,700)
  - 
  (142,700)
    
    
Ending balance
 $408,000 
 $154,300 
 $975,000 
 $600,000 
    

 
Investments in marketable securities classified as available-for-sale by security type at September 30, 2018March 31, 2019 and June 30, 2018 consisted of the following:
 
 Cost 
 Fair Value 
 Unrealized Holding Gain (Loss) 
At September 30, 2018:
   
   
   
Available for sale:
   
   
   
Equity securities
 $48,500 
 $76,800 
 $28,300 
Mutual funds
  262,800 
  245,900 
  (16,900)
 
    
    
    
 
 $311,300 
 $322,700 
 $11,400 
 
 
Cost
 
 
Fair Value
 
 
Unrealized Holding Gain (Loss)
 
At March 31, 2019:
 
 
 
 
 
 
 
 
 
Available-for-sale:
 
 
 
 
 
 
 
 
 
Equity securities
 $48,700 
 $74,700 
 $26,000 
Mutual funds
  288,700 
  250,400 
  (38,300)
 
    
    
    
 
 $337,400 
 $325,100 
 $(12,300)
 
 
 10
 Cost 
 Fair Value 
 Unrealized Holding Gain (Loss) 
 
Cost
 
 
Fair Value
 
 
Unrealized Holding Gain (Loss)
 
At June 30, 2018:
   
 
 
 
Available for sale:
   
Available-for-sale:
 
 
 
Equity securities
 $45,700 
 $67,800 
 $22,100 
 $45,700 
 $67,800 
 $22,100 
Mutual funds
  267,800 
  246,900 
  (20,900)
  267,800 
  246,900 
  (20,900)
    
    
 $313,500 
 $314,700 
 $1,200 
 $313,500 
 $314,700 
 $1,200 
 
 
5. Inventories
 
 
 September 30, 2018 
 June 30, 2018 
 
   
   
Raw materials
 $1,312,700 
 $1,488,000 
Work-in-process
  425,900 
  352,700 
Finished goods
  562,400 
  427,200 
 
    
    
 
 $2,301,000 
 $2,267,900 
Inventories are valued at the lower of cost (determined on a first-in, first-out basis) or net realizable value, and have been reduced by an allowance for excess and obsolete inventories. The estimate is based on management's review of inventories on hand compared to estimated future usage and sales. Cost of work-in-process and finished goods inventories include material, labor, and manufacturing overhead.
  

 
March 31, 2019
 
 
June 30, 2018

 
 
 
 
 
 
 
Raw materials
 $1,615,800 
 $1,488,000 
Work-in-process
  412,400 
  352,700 
Finished goods
  643,100 
  427,200 
 
    
    
 
 $2,671,300 
 $2,267,900 
 12

 
6.6. Goodwill and Other Intangible Assets
 
Goodwill represents the excess of the purchase price over the fair value of the net assets acquired in connection with the Company’s acquisitions. Goodwill amounted to $705,300 at September 30, 2018March 31, 2019 and June 30, 2018, all of which is expected to be deductible for tax purposes.
 
The components of other intangible assets are as follows:
 
Useful Lives
 Cost 
 Accumulated Amortization 
 Net 
At September 30, 2018: 
   
   
   
  
   
   
   
Technology, trademarks5/10 yrs.
 $662,800 
 $631,500 
 $31,300 
Trade names6 yrs.
  140,000 
  106,900 
  33,100 
Websites5 yrs.
  210,000 
  192,500 
  17,500 
Customer relationships9/10 yrs.
  357,000 
  298,100 
  58,900 
Sublicense agreements10 yrs.
  294,000 
  202,100 
  91,900 
Non-compete agreements5 yrs.
  384,000 
  361,500 
  22,500 
IPR&D3 yrs.
  110,000 
  110,000 
  - 
Other intangible assets
5 yrs.
  199,300 
  175,600 
  23,700 
 
    
    
    
 
 $2,357,100 
 $2,078,200 
 $278,900 
 
Useful
Lives
 
Cost
 
 
Accumulated Amortization
 
 
Net
 
At March 31, 2019: 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
Technology, trademarks5/10 yrs.
 $662,800 
 $661,600 
 $1,200 
Trade names6 yrs.
  140,000 
  118,600 
  21,400 
Websites5 yrs.
  210,000 
  210,000 
  - 
Customer relationships9/10 yrs.
  357,000 
  304,800 
  52,200 
Sublicense agreements10 yrs.
  294,000 
  216,800 
  77,200 
Non-compete agreements5 yrs.
  384,000 
  384,000 
  - 
IPR&D3 yrs.
  110,000 
  110,000 
  - 
Other intangible assets5 yrs.
  219,400 
  181,600 
  37,800 
 
    
    
    
 
 $2,377,200 
 $2,187,400 
 $189,800 
 
 
Useful Lives
 Cost 
 Accumulated Amortization 
 Net 
Useful
Lives
 
Cost
 
 
Accumulated Amortization
 
 
Net
 
 
   
 
 
 
 
At June 30, 2018: 
   
 
 
 
 
 
   
 
 
 
 
Technology, trademarks5/10 yrs.
 $662,800 
 $613,400 
 $49,400 
5/10 yrs.
 $662,800 
 $613,400 
 $49,400 
Trade names6 yrs.
  140,000 
  101,100 
  38,900 
6 yrs.
  140,000 
  101,100 
  38,900 
Websites5 yrs.
  210,000 
  182,000 
  28,000 
5 yrs.
  210,000 
  182,000 
  28,000 
Customer relationships9/10 yrs.
  357,000 
  294,800 
  62,200 
9/10 yrs.
  357,000 
  294,800 
  62,200 
Sublicense agreements10 yrs.
  294,000 
  194,800 
  99,200 
10 yrs.
  294,000 
  194,800 
  99,200 
Non-compete agreements5 yrs.
  384,000 
  348,000 
  36,000 
5 yrs.
  384,000 
  348,000 
  36,000 
IPR&D3 yrs.
  110,000 
  - 
3 yrs.
  110,000 
  - 
Other intangible assets
5 yrs.
  198,100 
  173,100 
  25,000 
5 yrs.
  198,100 
  173,100 
  25,000 
    
    
 $2,355,900 
 $2,017,200 
 $338,700 
 $2,355,900 
 $2,017,200 
 $338,700 
 
Total amortization expense was $61,000$47,900 and $61,100$61,200 for the three months ended September 30,March 31, 2019 and 2018, respectively and 2017,$170,200 and $183,400 for the nine months ended March 31, 2019 and 2018, respectively. As of September 30, 2018,March 31, 2019, estimated future amortization expense related to intangible assets is $125,900$16,600 for the remainder of the fiscal year ending June 30, 2019, $66,400 for fiscal 2020, $49,100 for fiscal 2021, $26,100 for fiscal 2022, $9,800 for fiscal 2023, and $1,600$21,800 thereafter.
 
 1113
 
 

7.7. IncomeEarnings (Loss) Per Common Share
 
Income (Loss)
Earnings (loss) per common share data was computed as follows:
 For the Three Months Ended September 30, 2018 
 For the Three Months Ended September 30, 2017 
 
For the Three Month Period Ended
March 31,
 2019
 
 
For the Three Month Period Ended
March 31,
 2018
 
 
For the Nine Month Period Ended
March 31,
2019
 
 
For the Nine Month Period Ended
March 31,
 2018
 
   
 
 
 
Net income (loss)
 $142,000 
 $(232,600)
 $93,600 
 $(37,700)
 $354,100 
 $(351,500)
    
    
Weighted average common shares outstanding
  1,494,112 
  1,494,112 
Effect of dilutive securities
  3,897 
  - 
  23,007 
  - 
  15,248 
  - 
Weighted average dilutive common shares outstanding
  1,498,009 
  1,494,112 
  1,517,119 
  1,494,112 
  1,509,360 
  1,494,112 
    
    
Basic earnings (loss) per common share
 $.10 
 $(.16)
 $.06 
 $(.03)
 $.24 
 $(.24)
    
Diluted earnings (loss) per common share
 $.09 
 $(.16)
 $.06 
 $(.03)
 $.23 
 $(.24)
 
Approximately 92,0001,750 and 82,000 shares of the Company's common stock issuable upon the exercise of outstanding options were excluded from the calculation of diluted earnings per common share for the three monthsand nine month periods ended September 30,March 31, 2019 and 2018, and 2017, respectively, because the effect would be anti-dilutive.
 
 12 14
 


IItemtem 2. Management's Discussion and Analysis of Financial Condition and Results of Operations
 

Forward-Looking statements. Certain statements contained in this report are not based on historical facts, but are forward-looking statements that are based upon various assumptions about future conditions. Actual events in the future could differ materially from those described in the forward-looking information. Numerous unknown factors and future events could cause such differences, including but not limited to, product demand, market acceptance, success of marketing strategy, success of expansion efforts, impact of competition, adverse economic conditions, and other factors affecting the Company’s business that are beyond the Company’s control, which are discussed elsewhere in this report. Consequently, no forward-looking statement can be guaranteed. The Company undertakes no obligation to publicly update forward-looking statements, whether as a result of new information, future events or otherwise. This Management’s Discussion and Analysis of Financial Condition and Results of Operations should be read in conjunction with the Company’s financial statements and the related notes included elsewhere in this report.
 
Overview.
Overview.The Company reflected income before income tax expense of $177,500$193,500 for the three months ended September 30, 2018March 31, 2019 compared to a loss before income tax benefit of $306,500$83,900 for the three months ended September 30, 2017,March 31, 2018, primarily due to an increase in earned royalties by the resultBioprocessing Systems Operations and reduced losses by the Catalyst Research Instruments Operations. The Company reflected income before income tax of increased$519,900 for the nine months ended March 31, 2019 compared to a loss before income tax benefit of $374,100 for the nine months ended March 31, 2018 due to increases in revenues and profits across all business segments.segments as described further under “Results of Operations”. The results reflected total non-cash amounts for depreciation and amortization and contingent consideration liability adjustments of $75$633,300 ,900and $785,200 for the three and $77,100nine month periods ended March 31, 2019 compared to $521,700 and $675,800 for the corresponding three months ended September 30, 2018 and 2017, respectively.nine month periods in 2018.
 
Results of Operations.Operations.
The Three Months Ended March 31, 2019 Compared with The Three Months Ended March 31, 2018
Net revenues for the three months ended September 30, 2018March 31, 2019 increased $757,800 (59.2%$954,200 (45.5%) to $2,038,600$3,053,500 from $1,280,800$2,099,300 for the three months ended September 30, 2017,March 31, 2018, reflecting an increaseincreased earned bioprocessing royalties of $492,500 (41.1%) in net$374,600, increased sales of catalyst research instruments of $397,900, and increased sales of benchtop laboratory equipment.equipment of $181,700. The benchtop laboratory equipment sales reflected $425,300$522,400 of Torbal brand product sales for the three months ended September 30, 2018,March 31, 2019 compared to $304,200$328,800 in the three months ended September 30, 2017 as a result of continued growthMarch 31, 2018. The Bioprocessing Systems Operations benefitted from increased royalties, primarily in Europe, and the Catalyst Research Instruments benefitted from increased sales of the new force gauges product line. Sales of catalyst research instruments increased by $188,800 to $217,500 for the three months ended September 30, 2018 compared to $28,700 for the three months ended September 30, 2017 because there were no large orders shipped during the prior year period.custom products. As of September 30, 2018,March 31, 2019, the order backlog for catalyst research instruments was $329,400,$834,300, substantially all of which is expected to be shippedship during the fiscal year ending June 30, 2019, compared to $323,900$1,175,800 as of September 30, 2017. Revenues derived from the Bioprocessing Systems Operations which comprise primarily of net royalties accrued from sublicensees increased by $76,500 (145.2%) to $129,200 for the three months ended September 30, 2018 compared to $52,700 for the three months ended September 30, 2017.March 31, 2018.
 
The overall gross profit percentage for the three months ended September 30, 2018March 31, 2019 was 46.4%35.4% compared to 35.3%36.6% for the three months ended September 30, 2017. The current period gross margin reflected increased gross profit margin percentage for the Benchtop Laboratory Operations as a result of higher sales and lower overhead costs. The gross profit margin percentage for catalyst research instruments was higher for the current period compared to the same period last year because the prior year period was negatively impacted by fixed overhead on significantly lower sales.March 31, 2018.
 
General and administrative expenses for the three months ended September 30, 2018 amountedMarch 31, 2019 increased by $22,200 (4.7%) to $416,500$492,400 compared to $428,400$470,200 for the three months ended September 30, 2017March 31, 2018, primarily due to various minor decreases inincreased routine legal expenses and fees paid to directors for Board of Directors meetings as compared to the Bioprocessing Systems Operations and the Catalyst Research Instruments Operations.same period last year.
 
Selling expenses for the three months ended September 30, 2018March 31, 2019 increased $35,100 (17.5%$18,300 (6.9%) to $236,100$282,100 from $201,000$263,800 for the three months ended September 30, 2017 primarilyMarch 31, 2018, due principally to increased sales and marketing activities by the Benchtop Laboratory Equipment Operations.commissions paid for catalyst research instruments sales.
 
Research and development expenses decreased by $11,700 (9.1%)amounted to $117,400$120,900 for the three months ended September 30, 2018March 31, 2019 compared to $129,100$117,700 for the three months ended September 30, 2017, primarily because of reduced new product development activities in the current year period for benchtop laboratory equipment.March 31, 2018.
 
Total other income, net was $1,800$7,800 for the three months ended September 30, 2018March 31, 2019 compared to $300$0 for the three months ended September 30, 2017,March 31, 2018 due primarily to unrealized holding gains on equityredemptions of investment securities.
 
The Company reflected income tax expense of $35,500$99,900 for the three months ended September 30, 2018March 31, 2019 compared to aincome tax benefit of $73,900$46,200 for the three months ended September 30, 2017,March 31, 2018, primarily due toresulting from the income generated duringfor the three months ended September 30, 2018.current period.
 
As a result of the foregoing, the Company recorded net income of $142,000$93,600 for the three months ended September 30, 2018March 31, 2019 compared to a net loss of $232,600($37,700) for the three months ended September 30, 2017.March 31, 2018.
    
 15
The Nine Months Ended March 31, 2019 Compared with The Nine Months Ended March 31, 2018
Net revenues for the nine months ended March 31, 2019 increased $1,982,700 (37.6%) to $7,255,300 from $5,272,600 for the nine months ended March 31, 2018, reflecting an increase of $791,200 in net sales of benchtop laboratory equipment resulting from increased orders for Genie and Torbal brand products, an increase of $660,200 in net sales of catalyst research instruments derived from sales of custom products, and an increase of $531,300 in bioprocessing earned royalties. The benchtop laboratory equipment sales reflected $1,406,400 of Torbal brand product sales for the nine months ended March 31, 2019, compared to $993,000 in the nine months ended March 31, 2018.
The overall gross profit percentage for the nine months ended March 31, 2019 was 41.4% compared to 37.7% for the nine months ended March 31, 2018 mainly as a result of the higher sales and improved gross margins by the Catalyst Research Instruments Operations and increased royalties earned by the Bioprocessing Systems Operations.
General and administrative expenses for the nine months ended March 31, 2019 increased $64,400 (4.9%) to $1,371,000 from $1,306,600 for the nine months ended March 31, 2018, mainly due to various increases in administrative expenses by the Benchtop Laboratory Equipment Operations, including routine legal expenses and fees paid to the directors for
Board of Directors meetings compared to the same period last year.
Selling expenses for the nine months ended March 31, 2019 increased $86,900 (12.8%) to $766,400 from $679,500 for the nine months ended March 31, 2018, due to increased online advertising for the Torbal product line and sales commissions related to the Benchtop Laboratory Equipment Operations.
Research and development expenses decreased by $32,100 (8.5%) to $347,600 for the nine months ended March 31, 2019 compared to $379,700 for the nine months ended March 31, 2018, primarily due to decreased new product development activities by the Benchtop Laboratory Equipment Operations related to the Torbal Scales Division’s new automated pill counter anticipated to be launched in autumn of 2019.
Total other income was $2,300 for the nine months ended March 31, 2019 compared to $6,400 for the nine months ended March 31, 2018 primarily due to lower income on investment securities.
The Company reflected income tax expense of $165,800 for the nine months ended March 31, 2019 compared to an income tax benefit of $22,600 for the nine months ended March 31, 2018, primarily due to the income during the period.
As a result of the foregoing, the Company recorded net income of $354,100 for the nine months ended March 31, 2019 compared to a net loss of ($351,500) for the nine months ended March 31, 2018.

Liquidity and Capital Resources. Cash and cash equivalents increased by $454,200$301,100 to $1,507,300$1,354,200 as of September 30, 2018March 31, 2019 from $1,053,100 as of June 30, 2018.2018 primarily due to income during the period.
 
Net cash provided by operating activities was $460,700$484,700 for the threenine months ended September 30, 2018March 31, 2019 compared to $103,600$150,200 used during the threenine months ended September 30, 2017, primarily as a resultMarch 31, 2018. The current period reflected higher income, and decreased change in the use of cash for inventories and accounts payable compared to the income for the current year period.last period, partially offset by change in accounts receivable balances. Net cash used in investing activities was $4,900$153,800 for the threenine months ended September 30, 2018March 31, 2019 compared to $41,500$88,600 used during the threenine months ended September 30, 2017 principallyMarch 31, 2018 primarily due to newincreased capital equipment purchasedpurchases during the prior yearcurrent period by the Benchtop Laboratory Equipment Operations. The Company used $1,600$29,800 in financing activities in the threenine months ended September 30, 2018March 31, 2019 compared to $144,300$107,700 in the threenine months ended September 30, 2017March 31, 2018 mainly due to the contingent consideration paidpayments of $142,700 in the prior year period.year.
 
The Company's working capital increased by $159,600$873,500 to $4,277,800$4,991,700 as of September 30, 2018March 31, 2019 compared to $4,118,200, as of June 30, 2018 primarily due to the income generated during the period.period.
 
The Company has a Demand Line of Credit through December 20182019 with First National Bank of Pennsylvania which provides for borrowings of up to $300,000 for regular working capital needs, bearing interest at prime, currently 5.25%5.50%. Advances on the line, are secured by a pledge of the Company’s assets including inventory, accounts, chattel paper, equipment and general intangibles of the Company.intangibles.  As of September 30, 2018 no borrowings wereMarch 31, 2019, $50,000 was outstanding under such line.the line which was repaid in April 2019.
 
Management believes that the Company will be able to meet its cash flow needs during the 12 months ending September 30, 2019March 31, 2020 from its available financial resources including the lines of credit, its cash and investment securities, and operations.
 

 1316
 
 
Item 4. Controls and Procedures
 
Evaluation of Disclosure Controls and Procedures. As of the end of the period covered by this report, based onthe Company's management performed an evaluation of the effectiveness of the Company's disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934),. Based on this evaluation, the Chief Executive and Chief Financial Officer of the Company has concluded that the Company's disclosure controls and procedures arewere not effective to ensure that information required to be disclosed by the Company in its Exchange Act reports is recorded, processed, summarized and reported within the applicable time periods specified by the SEC's rules and forms. The Company also concluded that information required to be disclosed in such reports is accumulated and communicated to the Company's management, including its principal executive and principal financial officer, as appropriate to allow timely decisions regarding required disclosure.
As a result of our adoptionMarch 31, 2019, because of the new revenue standard (Topic 606), we implemented controls to ensure adequate evaluationidentification of contracts and assessment of the impact of the new accounting standard related to revenue recognition on our financial statements to facilitate its adoption on July 1, 2018. There were no significant changes to oura material weakness in internal control over financial reporting duewhich related to the adoptionaccounting for the fair market value of a contingent consideration liability related to its Bioprocessing Systems Operations. Notwithstanding the material weakness that existed as of March 31, 2019, the Chief Executive and Chief Financial Officer of the new standard, as such term is definedCompany has concluded that the financial statements included in Exchange Act Rules 13a-15(f) and 15d-15(f) during the period covered by this Quarterly Report oron Form 10-Q present fairly, in other factors that have materially affected, or are reasonably likely to materially affect, our internal controls overall material respects, the financial reporting.position, results of operations, and cash flows of the Company and its subsidiaries in conformity with accounting principles generally accepted in the United States of America ("GAAP").
 
 
PPARTART II – OTHER INFORMATION
 
ItemItem 6. Exhibits and Reports on Form 8-K
 

Exhibit Number
 
Description
31.0
31.1
Certification of Chief Executive Officer and Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
32.13
Certification of Chief Executive Officer and Chief Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
 
Reports on Form 8-K: None
 
Report dated September 28, 2018 reporting under item 8.01
 
14  17
 
 
SIGNATURE
SIGNATURE
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
 
 
Date: November 13, 2018May 14, 2019
SCIENTIFIC INDUSTRIES, INC.
(Registrant)
 
/s/ Helena R. Santos
 
 
Helena R. Santos
President, Chief Executive Officer, Treasurer
Chief Financial and Principal Accounting Officer
 
 
 
  18
 15